GlassScriptPhysician profile
Shannon Case
NPI 1356913826
$5,769.50
in general payments reported to CMS, 2019-2025
34 companies · $788 in 2025
The $788 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,677 · 2023: $2,393 · 2024: $912 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,684 · Education: $409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.80 |
| Education | $408.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,304.88 | 2022-2025 | |
| Janssen Biotech, INC. | $601.99 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $598.48 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Amgen INC. | $570.62 | 2022-2024 | Otezla, Enbrel, Avsola |
| Mallinckrodt Hospital Products INC. | $398.27 | 2022-2023 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $274.66 | 2022-2025 | Sotyktu, Orencia |
| Glaxosmithkline, LLC. | $254.53 | 2022-2023 | Benlysta |
| Ucb, INC. | $230.49 | 2022-2024 | Cimzia, Bimzelx |
| Pfizer INC. | $206.50 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $193.91 | 2024-2025 | Dupixent |
| Sanofi-Aventis U.S. LLC | $177.00 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $170.94 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $143.98 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.73 | 2022-2023 | Cyltezo, Ofev |
| Alexion Pharmaceuticals, INC. | $57.39 | 2023 | Strensiq |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $51.85 | 2023-2025 | Renflexis, Vtama, Nexplanon |
| Astrazeneca Pharmaceuticals LP | $47.60 | 2022-2023 | Saphnelo |
| Galderma Laboratories, L.P. | $44.19 | 2024-2025 | Aklief, Nemluvio |
| Sobi, INC | $36.32 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $32.38 | 2023 | Purified Cortrophin Gel |
| Ferring Pharmaceuticals INC. | $29.92 | 2023 | Clenpiq |
| Incyte Corporation | $26.65 | 2024 | Opzelura |
| Fidia Pharma USA INC. | $25.43 | 2022-2023 | Triluron, Hymovis |
| Leo Pharma INC. | $23.22 | 2024 | Adbry |
| Takeda Pharmaceuticals U.S.A., INC. | $22.65 | 2022 | |
| Depuy Synthes Sales INC. | $22.00 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $21.17 | 2023 | Arcalyst |
| Actelion Pharmaceuticals US, INC. | $20.44 | 2023 | Uptravi |
| Horizon Therapeutics Plc | $18.35 | 2023 | Krystexxa |
| Sandoz INC. | $17.11 | 2023 | Hyrimoz |
| Radius Health, INC. | $16.96 | 2023 | |
| Genentech USA, INC. | $16.57 | 2023 | Actemra |
| Fresenius Kabi USA, LLC | $16.04 | 2023 | Idacio |
| Genzyme Corporation | $14.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.